New diabetes drug candidate enters early human testing
NCT ID NCT07270731
First seen Jan 11, 2026 · Last updated Apr 30, 2026 · Updated 22 times
Summary
This early-stage study tests a new medicine, NNC9733-0001, to see if it is safe and tolerable in healthy volunteers and people with type 2 diabetes. Participants receive either the study drug or a placebo as a single injection. The study lasts about 10 months and will monitor side effects and how the drug affects blood sugar.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Profil Institut für Stoffwechselforschung GmbH
RECRUITINGNeuss, 41460, Germany
Conditions
Explore the condition pages connected to this study.